International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH); Draft Guidance for Industry on Bracketing and Matrixing Designs for Stability Testing of New Veterinary Drug Substances and Medicinal Products (VICH GL45); Availability, 35875-35876 [E9-17251]
Download as PDF
Federal Register / Vol. 74, No. 138 / Tuesday, July 21, 2009 / Notices
McQuillan, Division of Health and
Nutrition Examination Surveys,
National Center for Health Statistics,
Centers for Disease Control and
Prevention, 3311 Toledo Road, Room
4204, Hyattsville, MD 20782, Phone:
301–458–4371; Fax: 301–458–4028, email: gmm2@cdc.gov.
Tanja Popovic,
Chief Science Officer, Centers for Disease
Control and Prevention.
[FR Doc. E9–17267 Filed 7–20–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0309]
International Cooperation on
Harmonisation of Technical
Requirements for Registration of
Veterinary Medicinal Products (VICH);
Draft Guidance for Industry on
Bracketing and Matrixing Designs for
Stability Testing of New Veterinary
Drug Substances and Medicinal
Products (VICH GL45); Availability
AGENCY:
Food and Drug Administration,
HHS.
jlentini on DSKJ8SOYB1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry (#198) entitled ‘‘Draft Guidance
for Industry on Bracketing and
Matrixing Designs For Stability Testing
of New Veterinary Drug Substances and
Medicinal Products,’’ VICH GL45. This
draft guidance has been developed for
veterinary use by the International
Cooperation on Harmonisation of
Technical Requirements for Registration
of Veterinary Medicinal Products
(VICH). This draft guidance is an annex
to a VICH guidance entitled ‘‘Stability
Testing of New Veterinary Drug
Substances and Medicinal Products
(Revision),’’ VICH GL3(R), that
published in the Federal Register of
November 23, 2007 (72 FR 65751). This
draft VICH guidance document is
intended to provide guidance on the
application of reduced designs (i.e.,
bracketing and matrixing) for stability
studies conducted in accordance with
the principles outlined in VICH GL3(R).
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance submit
VerDate Nov<24>2008
16:50 Jul 20, 2009
Jkt 217001
written or electronic comments on the
draft guidance by August 20, 2009.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Communications Staff (HFV–12), Center
for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your request.
Submit written comments on the draft
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
FOR FURTHER INFORMATION CONTACT:
Dennis Bensley, Center for Veterinary
Medicine (HFV–140), Food and Drug
Administration, 7500 Standish Place,
Rockville, MD 20855, 240–276–8268, email: dennis.bensley@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry (#198)
entitled ‘‘Draft Guidance for Industry on
Bracketing and Matrixing Designs for
Stability Testing of New Veterinary
Drug Substances and Medicinal
Products,’’ VICH GL45. In recent years,
many important initiatives have been
undertaken by regulatory authorities
and industry associations to promote
the international harmonization of
regulatory requirements. FDA has
participated in efforts to enhance
harmonization and has expressed its
commitment to seek scientifically based
harmonized technical procedures for the
development of pharmaceutical
products. One of the goals of
harmonization is to identify and then
reduce differences in technical
requirements for drug development
among regulatory agencies in different
countries.
FDA has actively participated in the
International Conference on
Harmonisation of Technical
Requirements for Approval of
Pharmaceuticals for Human Use for
several years to develop harmonized
technical requirements for the approval
of human pharmaceutical and biological
products among the European Union,
Japan, and the United States. The VICH
is a parallel initiative for veterinary
medicinal products. The VICH is
concerned with developing harmonized
technical requirements for the approval
of veterinary medicinal products in the
European Union, Japan, and the United
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
35875
States, and includes input from both
regulatory and industry representatives.
The VICH Steering Committee is
composed of member representatives
from: The European Commission,
European Medicines Evaluation Agency,
European Federation of Animal Health,
Committee on Veterinary Medicinal
Products, the U.S. FDA, the U.S.
Department of Agriculture, the Animal
Health Institute, the Japanese Veterinary
Pharmaceutical Association, the
Japanese Association of Veterinary
Biologics, and the Japanese Ministry of
Agriculture, Forestry, and Fisheries.
Four observers are eligible to
participate in the VICH Steering
Committee: One representative from the
government of Australia/New Zealand,
one representative from the industry in
Australia/New Zealand, one
representative from the government of
Canada, and one representative from the
industry of Canada. The VICH
Secretariat, which coordinates the
preparation of documentation, is
provided by the International
Federation for Animal Health (IFAH).
An IFAH representative also
participates in the VICH Steering
Committee meetings.
II. Draft Guidance on Bracketing and
Matrixing Designs for Stability Testing
The VICH Steering Committee held a
meeting on February 11, 2008, and
agreed that the draft guidance document
entitled ‘‘Draft Guidance for Industry on
Bracketing and Matrixing Designs for
Stability Testing of New Veterinary
Drug Substances and Medicinal
Products,’’ VICH GL45 should be made
available for public comment. This draft
VICH guidance document provides
guidance on bracketing and matrixing
study designs. Specific principles are
defined in this guidance for situations
in which bracketing or matrixing can be
applied. This document is intended to
address recommendations on the
application of bracketing and matrixing
to stability studies conducted in
accordance with principles outlined in
the VICH GL3(R), ‘‘Stability Testing of
New Veterinary Drug Substances and
Medicinal Products (Revision).’’ FDA
and the VICH Expert Quality Working
Group will consider comments about
the draft guidance document.
III. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
E:\FR\FM\21JYN1.SGM
21JYN1
35876
Federal Register / Vol. 74, No. 138 / Tuesday, July 21, 2009 / Notices
of information in sections 1–2 of this
guidance have been approved under
OMB Control No. 0910–0032.
IV. Significance of Guidance
This draft guidance, developed under
the VICH process, has been revised to
conform to FDA’s good guidance
practices regulation (21 CFR 10.115).
For example, the document has been
designated ‘‘guidance’’ rather than
‘‘guideline.’’ In addition, guidance
documents must not include mandatory
language such as ‘‘shall,’’ ‘‘must,’’
‘‘require,’’ or ‘‘requirement,’’ unless
FDA is using these words to describe a
statutory or regulatory requirement.
The draft guidance, when finalized,
will represent the agency’s current
thinking on this topic. It does not create
or confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of applicable statutes and
regulations.
V. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
VI. Electronic Access
Persons with access to the Internet
may obtain the draft guidance at either
https://www.fda.gov/cvm or https://
www.regulations.gov.
Dated: July 10, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–17251 Filed 7–20–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
jlentini on DSKJ8SOYB1PROD with NOTICES
[Docket No. FDA–2009–N–0664]
Risk Communication Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Nov<24>2008
16:50 Jul 20, 2009
Jkt 217001
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Risk
Communication Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on August 13, 2009, from 8 a.m. to
5 p.m. and August 14, 2009, from 8 a.m.
to 2 p.m.
Location: National Transportation
Safety Board (NTSB) Conference Center,
429 L’Enfant Plaza SW., Washington,
DC 20594 (at Metro’s L’Enfant Plaza
station; parking is limited and public
transportation is recommended.)
Contact Person: Lee L. Zwanziger,
Office of the Commissioner, Office of
Policy, Planning and Preparedness,
Office of Planning, Food and Drug
Administration, 5600 Fishers Lane, rm.
14–90, Rockville, MD 20857, 301–827–
2895, FAX: 301–827–4050, e-mail:
RCAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
8732112560. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On August 13 and 14, 2009,
the Committee will discuss FDA’s
external research on, and internal
assessment of, communications about
food safety problems. This discussion
will address research on consumer
knowledge of food recalls and plans for
how to monitor communication
effectiveness during the course of a
recall. The purpose of the discussion is
to advise FDA on developing more
effective communication strategies. Also
on August 14, 2009, the RCAC will be
briefed on the work of the FDA
Transparency Task Force.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm, click on the year 2009 and
scroll down to the appropriate advisory
committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before August 7, 2009. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. on August 13th and
10:30 to 11:30 a.m. on August 14th.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before August 6,
2009. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 7, 2009.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Lee L.
Zwanziger at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Dated: July 10, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9–17222 Filed 7–20–09; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\21JYN1.SGM
21JYN1
Agencies
[Federal Register Volume 74, Number 138 (Tuesday, July 21, 2009)]
[Notices]
[Pages 35875-35876]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-17251]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-D-0309]
International Cooperation on Harmonisation of Technical
Requirements for Registration of Veterinary Medicinal Products (VICH);
Draft Guidance for Industry on Bracketing and Matrixing Designs for
Stability Testing of New Veterinary Drug Substances and Medicinal
Products (VICH GL45); Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry (198) entitled
``Draft Guidance for Industry on Bracketing and Matrixing Designs For
Stability Testing of New Veterinary Drug Substances and Medicinal
Products,'' VICH GL45. This draft guidance has been developed for
veterinary use by the International Cooperation on Harmonisation of
Technical Requirements for Registration of Veterinary Medicinal
Products (VICH). This draft guidance is an annex to a VICH guidance
entitled ``Stability Testing of New Veterinary Drug Substances and
Medicinal Products (Revision),'' VICH GL3(R), that published in the
Federal Register of November 23, 2007 (72 FR 65751). This draft VICH
guidance document is intended to provide guidance on the application of
reduced designs (i.e., bracketing and matrixing) for stability studies
conducted in accordance with the principles outlined in VICH GL3(R).
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance submit written or electronic comments on the draft guidance by
August 20, 2009.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Communications Staff (HFV-12), Center for Veterinary
Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville,
MD 20855. Send one self-addressed adhesive label to assist that office
in processing your request.
Submit written comments on the draft guidance to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to https://www.regulations.gov. See the SUPPLEMENTARY INFORMATION
section for electronic access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT: Dennis Bensley, Center for Veterinary
Medicine (HFV-140), Food and Drug Administration, 7500 Standish Place,
Rockville, MD 20855, 240-276-8268, e-mail: dennis.bensley@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
(198) entitled ``Draft Guidance for Industry on Bracketing and
Matrixing Designs for Stability Testing of New Veterinary Drug
Substances and Medicinal Products,'' VICH GL45. In recent years, many
important initiatives have been undertaken by regulatory authorities
and industry associations to promote the international harmonization of
regulatory requirements. FDA has participated in efforts to enhance
harmonization and has expressed its commitment to seek scientifically
based harmonized technical procedures for the development of
pharmaceutical products. One of the goals of harmonization is to
identify and then reduce differences in technical requirements for drug
development among regulatory agencies in different countries.
FDA has actively participated in the International Conference on
Harmonisation of Technical Requirements for Approval of Pharmaceuticals
for Human Use for several years to develop harmonized technical
requirements for the approval of human pharmaceutical and biological
products among the European Union, Japan, and the United States. The
VICH is a parallel initiative for veterinary medicinal products. The
VICH is concerned with developing harmonized technical requirements for
the approval of veterinary medicinal products in the European Union,
Japan, and the United States, and includes input from both regulatory
and industry representatives.
The VICH Steering Committee is composed of member representatives
from: The European Commission, European Medicines Evaluation Agency,
European Federation of Animal Health, Committee on Veterinary Medicinal
Products, the U.S. FDA, the U.S. Department of Agriculture, the Animal
Health Institute, the Japanese Veterinary Pharmaceutical Association,
the Japanese Association of Veterinary Biologics, and the Japanese
Ministry of Agriculture, Forestry, and Fisheries.
Four observers are eligible to participate in the VICH Steering
Committee: One representative from the government of Australia/New
Zealand, one representative from the industry in Australia/New Zealand,
one representative from the government of Canada, and one
representative from the industry of Canada. The VICH Secretariat, which
coordinates the preparation of documentation, is provided by the
International Federation for Animal Health (IFAH). An IFAH
representative also participates in the VICH Steering Committee
meetings.
II. Draft Guidance on Bracketing and Matrixing Designs for Stability
Testing
The VICH Steering Committee held a meeting on February 11, 2008,
and agreed that the draft guidance document entitled ``Draft Guidance
for Industry on Bracketing and Matrixing Designs for Stability Testing
of New Veterinary Drug Substances and Medicinal Products,'' VICH GL45
should be made available for public comment. This draft VICH guidance
document provides guidance on bracketing and matrixing study designs.
Specific principles are defined in this guidance for situations in
which bracketing or matrixing can be applied. This document is intended
to address recommendations on the application of bracketing and
matrixing to stability studies conducted in accordance with principles
outlined in the VICH GL3(R), ``Stability Testing of New Veterinary Drug
Substances and Medicinal Products (Revision).'' FDA and the VICH Expert
Quality Working Group will consider comments about the draft guidance
document.
III. Paperwork Reduction Act of 1995
This draft guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections
[[Page 35876]]
of information in sections 1-2 of this guidance have been approved
under OMB Control No. 0910-0032.
IV. Significance of Guidance
This draft guidance, developed under the VICH process, has been
revised to conform to FDA's good guidance practices regulation (21 CFR
10.115). For example, the document has been designated ``guidance''
rather than ``guideline.'' In addition, guidance documents must not
include mandatory language such as ``shall,'' ``must,'' ``require,'' or
``requirement,'' unless FDA is using these words to describe a
statutory or regulatory requirement.
The draft guidance, when finalized, will represent the agency's
current thinking on this topic. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of applicable statutes and regulations.
V. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
VI. Electronic Access
Persons with access to the Internet may obtain the draft guidance
at either https://www.fda.gov/cvm or https://www.regulations.gov.
Dated: July 10, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-17251 Filed 7-20-09; 8:45 am]
BILLING CODE 4160-01-S